SCD
56 programs · 54 companies
Programs
56
Companies
54
Trials
57
MOAs
36
BiTEAnti-TauBTKiIL-13iCFTR ModulatorCGRPantCAR-T CD19STINGagGLP-1/GIPKRASG12Ci
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-3251 | Phase 2 | MDM2 | ||
| NVS-5439 | Preclinical | BET | ||
| AZN-8281 | Phase 1 | SHP2 | ||
| BMY-4586 | Preclinical | KRASG12C | ||
| Exagamglogene autotemcel | Approved | BCL11A | ||
| Sematapinarof | NDA/BLA | VEGF | ||
| Talasotorasib | Preclinical | APOC3 | ||
| ILM-4317 | NDA/BLA | TROP-2 | ||
| EME-6317 | Approved | SOS1 | ||
| Gelirelsin | Phase 2 | KIF18A | ||
| ATO-3461 | Phase 1 | BCL-2 | ||
| GIM-IIT-532 | Phase 1/2 | KRASG12D | ||
| KAR-3569 | NDA/BLA | CDK2 | ||
| Voxazumab | Phase 1 | CD38 | ||
| Rimaglumide | Phase 2 | IL-13 | ||
| INO-2656 | Approved | WEE1 | ||
| FLA-9061 | NDA/BLA | JAK2 | ||
| ARC-5137 | Approved | IL-23 | ||
| PBL-8716 | Preclinical | GLP-1R | ||
| Bemarelsin | NDA/BLA | CD123 | ||
| Tixatenlimab | Approved | GIP-R | ||
| TAR-8916 | Phase 1 | LAG-3 | ||
| Tiracagene | Phase 3 | SOS1 | ||
| Surasacituzumab | Phase 3 | AuroraA | ||
| Elrazanubrutinib | NDA/BLA | Menin | ||
| Niratapinarof | Phase 2/3 | B7-H3 | ||
| Rilunaritide | Preclinical | CD3 | ||
| RGN-9803 | NDA/BLA | RET | ||
| Cevimavacamten | Phase 1/2 | FcRn | ||
| Polanesiran | Phase 1 | CD123 | ||
| 459-1094 | Phase 3 | BTK | ||
| 051-2746 | Phase 2/3 | CFTR | ||
| BIO-4284 | Phase 2/3 | PSMA | ||
| 532-4982 | Phase 3 | CDK4/6 | ||
| LAU-4167 | NDA/BLA | AHR | ||
| Gozetenlimab | NDA/BLA | Tau | ||
| Datorasimod | Phase 2/3 | CDK4/6 | ||
| Kemavorutinib | Approved | JAK2 | ||
| Voxainavolisib | Preclinical | BCMA | ||
| BSL-7024 | Phase 1 | WRN | ||
| Sovafutibatinib | Phase 1/2 | SHP2 | ||
| AAR-3535 | Phase 3 | Aβ | ||
| Talatenlimab | Approved | MET | ||
| Rimalucimab | Phase 2/3 | KIF18A | ||
| PRI-IIT-296 | NDA/BLA | EZH2 | ||
| SEV-IIT-824 | Phase 2 | PARP | ||
| Gozefutibatinib | NDA/BLA | WRN | ||
| Niraratamab | Phase 2/3 | RET | ||
| Lisozasiran | NDA/BLA | VEGF | ||
| ANG-192 | Phase 3 | CD47 | ||
| Darasertib | Phase 1/2 | PI3Kα | ||
| BLC-3714 | Approved | CD38 | ||
| Ivosotorasib | Phase 2/3 | EZH2 | ||
| ELA-3520 | Phase 2 | CD19 | ||
| Surarasimod | Phase 2 | BET | ||
| Gozeosocimab | Phase 1/2 | FLT3 |
Trials (57)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT03203219 | LLY-3251 | Phase 2 | Terminated |
| NCT05132136 | LLY-3251 | Phase 2 | Not yet recr... |
| NCT05686249 | NVS-5439 | Preclinical | Terminated |
| NCT08559633 | BMY-4586 | Preclinical | Not yet recr... |
| NCT03244024 | BMY-4586 | Preclinical | Active |
| NCT08376011 | Exagamglogene autotemcel | Approved | Completed |
| NCT04476536 | ILM-4317 | NDA/BLA | Active |
| NCT08145811 | ILM-4317 | NDA/BLA | Not yet recr... |
| NCT03746415 | EME-6317 | Approved | Not yet recr... |
| NCT07755130 | Gelirelsin | Phase 2 | Active |
| NCT03456778 | ATO-3461 | Phase 1 | Terminated |
| NCT05370496 | ATO-3461 | Phase 1 | Not yet recr... |
| NCT07575755 | GIM-IIT-532 | Phase 1/2 | Terminated |
| NCT06259974 | Voxazumab | Phase 1 | Completed |
| NCT05325730 | Rimaglumide | Phase 2 | Recruiting |
| NCT03034754 | INO-2656 | Approved | Terminated |
| NCT03045856 | INO-2656 | Approved | Recruiting |
| NCT04526575 | FLA-9061 | NDA/BLA | Recruiting |
| NCT06427650 | FLA-9061 | NDA/BLA | Active |
| NCT04115043 | ARC-5137 | Approved | Completed |